Safety and Efficacy of Giredestrant ± Palbociclib ± LHRH Agonists in Patients With ER+/HER2− Locally Advanced/Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase Ia/b Study of Giredestrant ±Palbociclib and ±Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer
Clin. Cancer Res 2023 Nov 03;[EPub Ahead of Print], KL Jhaveri, M Bellet-Ezquerra, NC Turner, S Loi, A Bardia, V Boni, J Sohn, TG Neilan, R Villanueva-Vázquez, P Kabos, L García Estévez, E Lopez-Miranda, JA Perez Fidalgo, JM Perez-Garcia, J Yu, J Fredrickson, HM Moore, CW Chang, JW Bond, J Eng-Wong, MR Gates, E LimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.